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license (http://creativecognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reli-
ability and feasibility of use.
Methods: We performed a test–retest study with 2–3 weeks between assessments, including patients
with mild cognitive impairment (MCI) or mild AD dementia and cognitively healthy participants. We
calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures
and compared baseline and retest scores using paired-samples t-tests. We evaluated feasibility by in-
terviewing participants.
Results: Forty-three patients (40% female, mean age 5 69.9) and 30 controls (50% female, mean
age5 65) were included. Subtest intraclass correlation coefficients ranged from .70 to .96. We found
negligible improvements after retesting on only two subtests. Overall, patients perceived the admin-
istration of the CFC as feasible.
Discussion: The CFC is a stable and feasible measure in MCI and mild AD dementia, and thereby
meets important quality metrics for clinically meaningful outcome measures.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Activities of daily living; Alzheimer’s disease; Cognition; Feasibility; Test–retest reliability; Outcome measures1. Introduction
Neurodegenerative diseases leading to dementia are
characterized by progressive cognitive decline and
increasing interference in daily function [1]. Alzheimer’s
disease (AD), which is the main cause of dementia world-
wide, is a continuum starting with a preclinical phase inthor. Tel.: 131 20 4448527.
utten@vumc.nl
/j.dadm.2017.12.002
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).which pathology develops but clinical symptoms are still
absent [2]. It can be accompanied by subjective complaints
as the first signal of the disease [3,4]. Cognitive deficits
become more prominent in the prodromal phase of mild
cognitive impairment (MCI) [5] and are ultimately severe
enough to interfere with daily life in the dementia stage
[6]. Measuring cognition and everyday functioning across
the AD continuum is pivotal for monitoring clinical pro-
gression and evaluating both symptomatic relief and
disease-modifying therapies. Currently used cognitive andimer’s Association. This is an open access article under the CC BY-NC-ND
R.J. Jutten et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 153-160154functional measures have shown to be of insufficient qual-
ity for these purposes, due to their insensitivity to clinically
meaningful changes over time [7]. For example, widely
used tests such as the Mini–Mental State Examination
(MMSE) [8] and the Alzheimer’s Disease Assessment
Scale–cognitive subscale (ADAS-Cog) [9] have been shown
to be inappropriate for use in the design and evaluation of
clinical trials targeted at MCI and mild AD [10–13].
As to the measurement of everyday functioning, recent
reviews pointed out that most commonly used
questionnaires are only of limited use to detect the early
functional decline [14,15].
Consequently, many researchers have expressed the
need for an improved measure that is capable of detecting
clinically meaningful changes in MCI and mild AD
[16,17]. To this end, the “Capturing Changes in
Cognition” (Catch-Cog) project was initiated [18]. Based
on preparatory work [19,20] and input from patients and
experts, we designed a novel composite assessment
combining measures of cognition and function: the
“cognitive-functional composite” (CFC) [18]. The CFC
comprises existing cognitive tests focusing on the domains
that are known to be vulnerable to decline in incipient AD,
specifically episodic memory (EM), working memory
(WM), and executive functioning (EF) [17]. To amplify
its clinical relevance, the CFC encompasses an everyday
functioning questionnaire focusing on instrumental activ-
ities of daily living (IADL) [20,21]. IADL are activities
that require the use of multiple cognitive processes and
include activities such as cooking, driving, and managing
finances. Difficulties in IADL performance are among the
earliest clinical symptoms in MCI and mild AD dementia
[15,22].
The present study reports on the first validation step of
the novel CFC, in which we focused on its stability and
feasibility. First, we investigated test–retest reliability of
the CFC subtests. Second, we examined the influence of
potential practice effects on the cognitive parts. Practice
effects are improvements in cognitive test performance
that may result from repeated exposure [23]. They are a
potential threat for longitudinal cognitive assessment, as
they can result in either underestimation of actual cogni-
tive decline or overestimation of real treatment effects
[24]. It is therefore important to explore the presence of
practice effects on novel outcome measures designed for
longitudinal use, such as the CFC. Previous studies on
the presence of practice effects on cognitive tests in indi-
viduals with and without cognitive impairment have
shown contrasting results [23–27]. Consequently, we
explored potential practice effects on the CFC subtests
separately for individuals with MCI or mild AD
dementia and cognitively healthy individuals. Third, we
computed an overall CFC score including all subtests.
We investigated whether this score was influenced by
age or education, and we examined the stability of this
score in both groups. Finally, we evaluated feasibility ofthe CFC, with a focus on patients’ experiences with
respect to its administration time, modality, and
perceived burden.2. Methods
2.1. Study design
This study is a multicenter, observational, prospective
cohort study, conducted at three Dutch sites and one United
Kingdom (UK) site. We used a test–retest design with 2–
3 weeks between assessments. Data were collected between
November 2015 and November 2016. The Medical Ethical
Committee of the VU University Medical Center (VUmc)
approved the study for all Dutch centers. The South East
Scotland Research Ethics Committee approved the study
for the UK site. All participants and study partners gavewrit-
ten informed consent.
2.2. Participants
We included patients with a clinical diagnosis of MCI
or probable AD dementia (n 5 48) and cognitively
healthy participants (n 5 30) with their study partners.
Patients were recruited via the VUmc Alzheimer Center
Amsterdam, the Spaarne Gasthuis Haarlem, the Alz-
heimer Center Rotterdam, the University Medical Center
Groningen, and the Centre for Dementia Prevention at
the University of Edinburgh. Before inclusion in the pre-
sent study, all patients had undergone a screening assess-
ment including medical history, neurological, and
neuropsychological examination in their center. Diagno-
ses were made in a multidisciplinary meeting containing
at least a neurologist, psychiatrist or geriatrician
and with neuropsychology input. MCI and probable
AD were diagnosed according to the corresponding
National Institute of Aging-Alzheimer’s Association
core clinical criteria [5,6]. Biomarkers (structural brain
imaging or cerebrospinal fluid) were available for
most but not all patients and were used to increase or
decrease the likelihood of AD according to McKhann
et al [6]. If not available, we relied on the clinical
diagnosis of MCI and AD. Other inclusion criteria
were as follows: (1) MMSE score  18 [8]; (2)
age  50; and (3) availability of a study partner (i.e. a
spouse, relative, or close friend) who was capable
and willing to participate. Exclusion criteria were as fol-
lows: (1) neurological or psychiatric diagnoses other
than AD (Geriatric Depression Scale score  6 [28]);
(2) current or a history of substance abuse; or (3) partic-
ipation in a clinical trial during the timeframe of the pre-
sent study.
Cognitively healthy participants originated from an exist-
ing healthy volunteer database from the VUmc Alzheimer
Center. Eligible participants had (1) an age  50; (2) neuro-
psychological test results within age- and education-
adjusted norms; and (3) an available study partner.
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The CFC was designed by the Catch-Cog working group
[18]. It comprises seven existing, validated cognitive tests.
Three EM tests originate from the ADAS-Cog [9]. These
include the following: (1) Word Recognition, for which a
participant has to learn a list of 12 words and identify these
words when mixed among 12 other distracter words (one
point for each incorrect response, score range 0–12); (2)
Orientation, containing eight questions regarding the partic-
ipant’s orientation to person, place, and time (one point for
each incorrect response, score range 0–8); and (3) Word
Recall, where the participant is given three trials to learn a
list of 10 high-imagery nouns (total score entails the average
number of words not recalled across the three trials, score
range 0–10). Other subtests originate from the neuropsycho-
logical test battery (NTB) and address different aspects of
EF [29–31]. These include the following: (4) the
Controlled Oral Word Association Test (COWAT),
assessing the participant’s phonological fluency skills
using the letters D-A-T (F-A-S in the UK) and a total time
of 60 seconds per letter (one point for each correct
nonrepeated word); and (5) the Category Fluency Test,
examining the participant’s semantic fluency by generating
as many animals within 60 seconds (one point for each
correct unique animal). First results show this combination
of three ADAS-Cog and two NTB tests to be a reliable com-
posite measure in MCI and mild AD, with good internal con-
sistency (Cronbach’s alpha 5 .80) and good test–retest
reliability at 4 (r 5 .89), 12 (r 5 .85), 18 (r 5 .84), and
24 weeks (r 5 .84) [19]. To cover the WM and EF domains
more broadly, the following tests were additionally included:
(6) the Wechsler Memory Scale Digit Span backward [32],
demanding a participant to reproduce sequences of digits
of increasing length in the reversed order (score range 0–
12); and (7) the Wechsler Digit Symbol Substitution Test
(DSST) [33], a timed EF test for which participants have
to substitute as many digits by unique geometric symbols
within 90 seconds (one point for each correct substituted
symbol).
The functional part of the CFC consists of the Amsterdam
IADL Questionnaire (A-IADL-Q): a computerized,
informant-based questionnaire covering a broad range of
cognitive IADL [20]. The A-IADL-Q consists of 70 items,
which can be divided into eight subcategories: household,
administration, work, computer use, leisure time, appliances,
transport, and other activities. For each item, difficulty in per-
formance is rated on a 5-point Likert scale (ranging from “no
difficulty in performing this task” to “no longer able to
perform this task”). Scoring is based on item response theory,
a paradigm linking item responses to an underlying latent
trait [34]. For the A-IADL-Q, this latent trait reflects IADL
impairment. Total A-IADL-Q scores are normally distrib-
uted (M 5 50, standard deviation [SD] 5 10), with lower
scores reflecting more IADL impairment. Previous work
showed that the A-IADL-Q has excellent psychometric qual-ities: factor analysis supported unidimensionality, high
internal consistency (reliability coefficient: .97), and good
test–retest reliability (k values. .60 for 87.9% of the items)
[20]. Avalidation study showed medium to high correlations
with other measures of cognition and everyday functioning,
suggesting good construct validity [21]. In addition, a longi-
tudinal validation study demonstrated that the A-IADL-Q
was sensitive to changes over time [35].
2.3.1. Feasibility interview
We evaluated the overall feasibility of the cognitive
component by interviewing a subsample of the patient group
(n5 15). These were all patients originating from the VUmc
Alzheimer Center. The interviews contained open, neutrally
formulated questions about the patient’s general impression
of the assessment. Subsequently, patients were asked to
share their thoughts on specific aspects, such as total admin-
istration time, perceived burden and difficulty level, and
quality of the test materials. If they addressed other issues
that were important for them, we invited them to elaborate
on these topics as well.2.4. Procedures
Assessments took place at either the hospital or the partic-
ipant’s home, depending on the participant’s preference. A
trained rater assessed the cognitive tests according to stan-
dardized instructions, in the following order: Word Recogni-
tion, Orientation, COWAT, Category Fluency Test, Digit
Span backward DSST, and Word Recall. In total, this took
approximately 20–25 minutes. In the meantime, the study
partner completed the A-IADL-Q independently on a tablet
computer in a separate room, which took about 20–25 mi-
nutes as well. Baseline and retest assessments had similar
content for participants and study partners, except that paral-
lel forms of the wordlists for Word Recognition and Word
Recall were used. Feasibility interviews were held directly
after the retest assessment. Before the start of the interview,
we mentioned that the test was still in development, and we
explicitly invited participants to mention aspects for
improvement if they had any.2.5. Statistical analyses
Statistical analyses were performed using SPSS, version
22.0. Statistical significance was set at P , .05. Demo-
graphic differences were investigated using independent-
samples t-tests or chi-square tests as appropriate. For the
subtest analyses, we used the raw test scores for the cognitive
measures and the total A-IADL-Q score, which were all un-
adjusted for age and education. We investigated test–retest
reliability for all individual subtests using intraclass correla-
tion coefficients (ICCs), using a two-way randommodel and
type absolute agreement. ICCs . .70 were considered
acceptable [36]. For subtests with lower ICCs, we applied
the Bland–Altman method to explore systematic differences
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with difference between baseline and retesting as dependent
variable and the average score of baseline and retesting as
independent variable [37]. To investigate potential practice
effects, we compared baseline and retest scores for all cogni-
tive subtests in the separate groups using paired-samples
t-tests or Wilcoxon signed-rank test as nonparametric alter-
native. Subsequently, we calculated Cohen’s d effect-sizes
for change scores. For subtests showing a significant change
score, we performed multiple linear regression analyses with
change score as dependent variable, and age and education
as independent variables, which were stepwise entered into
the model based on strength of their correlation with depen-
dent variable.
To create an overall CFC score, we first reversed the
ADAS-Cog subtest scores so that higher scores reflected bet-
ter performance. Subsequently, all subtest baseline and retest
scores were converted into Z-scores with baseline means and
SDs of the total group as reference values, and added up to an
overall CFC score. We investigated whether baseline CFC
scores differed between patients and controls using an
independent-samples t-test. We investigated possible associ-
ations with age or education by computing Pearson’s corre-
lation coefficients or Spearman’s rho if appropriate. We
examined stability of the CFC scores using the same test–re-
test analyses as described previously.3. Results
3.1. Demographic characteristics
Five participants (all patients, mean age 69.2, n 5 1 fe-
male) withdrew from the study before their retest visit due
to personal reasons and were therefore excluded from the an-
alyses. They did not differ from the other patients with
respect to demographics. The remaining patients (n 5 43,
40% female) had a mean age of 69.9 (SD 5 7.4), a meanTable 1
Demographic characteristics of participants and their study partners,
separate for the patient and control group
Characteristics
Patients
(n 5 43)
Controls
(n 5 30) P value
Participants
Female (%) 17 (40) 15 (50) .376y
Age (SD) 69.9 (7.4) 65.0 (7.1) .006*
Years of education (SD) 14.3 (5.1) 16.9 (4.0) .022*
MMSE (SD) 25.2 (3.2) NA
Study partners
Female (%) 28 (65) 19 (63) .876y
Age (SD) 66.9 (9.8) 62.5 (10.2) .070*
Relationship partner (%) 37 (86) 23 (77)
Relationship . 10 years (%) 42 (98) 30 (100)
Abbreviations: SD, standard deviation; MMSE, Mini–Mental State Ex-
amination; NA, not assessed.
*Tested using independent t-test.
yTested using chi-square test.MMSE score of 25.3 (SD 5 3.3), and received 14.3
(SD 5 5.1) years of education. Controls (n 5 30, 50% fe-
male) were slightly younger (M 5 65, SD 5 7.1,
P 5 .006) and marginally more highly educated
(M5 16.9, SD5 4.0, P5 .022) than patients (see Table 1).3.2. Test–retest reliability
Table 2 presents the ICCs for all subtests, which ranged
from .70 to .96. Word Recognition was the only subtest with
a borderline ICC of .70. The corresponding Bland–Altman
plot showed an equal number of data points above and below
the mean difference line, revealing no systematic differences
between the two measurements (Fig. 1). This was supported
by the regression analysis that showed no significant linear
relationship among the data points (b 5 .104, t 5 1.407,
P 5 .164). When looking at the distribution of data points
for the distinct groups, the Bland–Altman plot showed that
the control group had many similar scores and low between-
subject variance which probably influenced the ICC.
3.2.1. Practice effects
Table 2 also shows the ranges, baseline, and retest scores
of the individual subtests. In the patient group, we only found
a significant higher score after retesting for the DSST
(observed change512.4, SD5 5.2,P5.005). In the control
group, we found a significant higher score after retesting for
theDSST (observed change512.8, SD5 5.5,P5.011) and
COWAT (observed change512.5, SD5 7.8,P5.012). The
corresponding effect-sizes of these changes scores fell in the
low to medium range (Table 2). Regression analyses showed
that COWAT and DSST change scores were not confounded
by age or education: all regression coefficients were nonsig-
nificant (Table 3).
3.2.2. CFC score
Figure 2 displays the distribution of baseline CFC scores
for patients and controls. Mean score significantly differed
between groups (mean difference 5 9.7, SD 5 .8,
t5 12.12, P, .001). We found no associations with age (pa-
tients: r5 .09, P5 .573; controls: r52.18, P5 .35) or ed-
ucation (patients: r 5 .14, P 5 .378; controls: r 5 2.01,
P 5 .946) and baseline CFC score. The last row in Table 2
presents the mean CFC scores at baseline and retesting. We
found no significantly different CFC score at retest for pa-
tients, whereas in controls, the CFC scorewas slightly higher
after retesting (observed change51.9, SD5 1.5,P5 .006).3.3. Feasibility
Patients’ general impressions of the CFC were mainly
positive (e.g. described as “interesting”, “enjoyable”, and
“relevant”), although some patients described the test as
“challenging” or “confronting”. Some specific subtests
were frequently defined as “difficult”, particularly the tests
involving word lists. The majority stated that they did not
Table 2
Subtest characteristics: ICC’s, score ranges, and mean scores in the patient and control group
Measure
Total group
ICCs Score range
Patients Controls
Baseline (SD) Retest (SD) P value Cohen’s d Baseline (SD) Retest (SD) P value Cohen’s d
ADAS-Cog Word Recognition .70 0–12 4.6 (2.8) 4.8 (3.1) .684y .07 1.2 (1.3) 0.7 (1.1) .097y .40
ADAS-Cog Orientation .72 0–4 1.1 (1.3) 1.2 (1.3) .728y .08 0.0 (0.2) 0.1 (0.3) .564y .12
COWAT (DAT/FAS, 60 sec) .85 4–69 31.7 (13.3) 33.7 (14.4) .067* .15 42.9 (10.6) 45.4 (8.7) .012y .26
CFT (animals, 60 sec) .83 4–35 13.7 (5.7) 14.4 (5.7) .260* .12 24.2 (5.0) 25.3 (4.7) .185* .23
DSST (90 sec) .93 3–73 31.1 (11.7) 33.5 (11.4) .005* .21 52.4 (9.6) 55.2 (11.0) .011* .28
DSB .72 2–12 5.5 (1.5) 5.5 (2.0) .561y .04 6.7 (1.6) 7.2 (2.0) .081* .28
ADAS-Cog Word Recall .89 0–9 5.6 (1.5) 5.8 (1.4) .192y .14 2.5 (1.22) 2.7 (1.2) .141y .17
A-IADL-Q .96 22.8–76.0 49.7 (10.4) 49.8 (10.4) .830* NA 71.2 (4.8) 71.8 (3.7) .432* NA
Overall CFC score .95 214.9 to 12.36 23.9 (4.3) 23.7 (4.3) .412* NA 5.7 (2.4) 6.6 (2.7) .006* NA
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale–cognitive subscale; ICC, intraclass correlation coefficient; SD, standard deviation;
COWAT, Controlled Oral Word Association Test; CFT, Category Fluency Test; DSST, Digit Symbol Substitution Test; DSB, Digit Span backward; A-IADL-Q,
Amsterdam Instrumental Activities of Daily Living Questionnaire; CFC, cognitive-functional composite; NA, not assessed for this score.
*Tested using paired-samples t-test.
yTested using Wilcoxon rank-sign test.
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the total duration (20–25 minutes) was experienced as
acceptable. Patients’ descriptions of their ability to concen-
trate on the entire test ranged from “reasonable” to “very
good”. Test materials were described as “clear” and “very
readable”.4. Discussion
We addressed the stability and feasibility of the CFC by
performing a test–retest study and collecting input from par-
ticipants. Our findings demonstrated that all CFC compo-
nents had moderate to high test–retest reliability and wereAverage of baseline and retest score
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Fig. 1. Bland–Altman plot for subtest ADAS-Cog Word Recognition.
Abbreviation: ADAS-Cog, Alzheimer’s Disease Assessment Scale–cogni-
tive subscale.only limitedly affected by practice effects. We showed that
the overall CFC scorewas not influenced by age or education
and provided a stable measure especially for patients.
Finally, qualitative interviews indicated that patients
perceived the administration of the CFC overall as feasible.
The present study expands on previous work on the cognitive
composite [19] and A-IADL-Q [20], which form the under-
lying basis of the CFC. Our findings with respect to test–re-
test reliability of the CFC components are largely in line
with these former validation studies.
Our findings regarding practice effects in the patient
group are similar to previous research, whereas our findings
in the control group were somewhat different compared with
other studies. In patients, we found limited presence of prac-
tice effects, which was also reported earlier [23,26]. We only
observed a significant improvement on the DSST; however,
the clinical meaningfulness of the extent of this change (only
two points) seems negligible. A slight improvement on the
DSST in patients with AD seems to be a robust finding
because other studies observed this as well [24]. In the
cognitively healthy group, we only observed small practice
effects on the DSSTand COWAT. This is somewhat different
from previous studies demonstrating larger practice effects
on a wide variety of cognitive tests in cognitively healthy
adults, for example on word list tasks, category fluency,
and digit span backward [23,24]. A possible explanation
for the current findings is that most tests showed ceiling
effects in baseline scores of the control group, making it
by definition impossible to further improve these scores
and to observe a potential practice effect. Furthermore, the
use of parallel versions for the word lists tasks may have
limited the magnitude of practice effects in our study, in
both patients and controls [27].
Strengths of this study include the use of a prospective
cohort to investigate the CFC’s test–retest reliability. An in-
dependent validation of promising measures outside of the
Table 3
Regression coefficients for age and education on change scores for the
DSST and COWAT
Measure
Patients Controls
b t P value b t P value
DSST
Education 2.238 21.511 .139 .206 1.086 .287
Age 2.090 2.573 .570 .150 .790 .436
COWAT
Education NA .122 .642 .526
Age NA .123 .649 .522
Abbreviations: DSST, Digit Symbol Substitution Test; COWAT,
Controlled Oral Word Association Test; NA, not applicable for this group.
R.J. Jutten et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 153-160158larger, retrospective data sets in which they were designed is
a key requirement for any proposed new measure. In addi-
tion, the involvement of participants to evaluate feasibility
of our measurement is a unique and important aspect of
this study. An important advantage of this qualitativemethod
is that it allows participants to address topics that we had not
considered on forehand [38]. Our semi-structured interview
allowed us to ask more in-depth questions on topics that
appear to be relevant, which contributes to a more compre-
hensive understanding of the participant’s thoughts and be-
liefs [39]. Ultimately, acceptability by the target
population is highly important as it may contribute to future
implementation of the CFC.
There are however some limitations that should be consid-
ered. First, wewere not able to investigate theCFC separately
in theMCI andmild AD dementia group due to our relatively
small sample size, which was based on recommendations for
test–retest studies [40]. Validating the CFC in a larger cohort,
including bothMCI andmildADpatients, is however needed
and will be the scope of a future study addressing the longi-
tudinal psychometric properties of the CFC [18]. This larger
cohort will also allow us to explore whether the CFC scoreDiagnostic group
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Fig. 2. Boxplots displaying baseline CFC scores separately for patients and
controls. Abbreviation: CFC, cognitive-functional composite.further improves if the components are weighted differently
[41]. Second, the etiology ofADwas not confirmed for all pa-
tients with MCI because some of them had no biomarkers
available. In these cases, we relied on the clinical diagnosis,
and we excluded patients with other neurological or psychi-
atric symptoms to ensure that MCI was not attributable to
these factors. Third, our control and patient group were not
equallymatchedwith respect to age and education. However,
we showed that practice effects were not confounded by ed-
ucation and age nor was our CFC score, indicating that this
has probably not influenced our results. Finally, our study
involved only one repeated measurement, whereas other
studies on practice effects included more measurements
over a larger time period [23,25,26]. However, these
studies have shown that practice effects seem to be most
prominent after the first repeated measurement. Our finding
that the CFC only shows negligible practice effects after
testing the second time around is thus promising for any
additional repeated assessments.
In conclusion, we demonstrated that the CFC is a stable
and feasible measure in MCI and mild AD dementia. It
thereby meets important quality metrics for clinically mean-
ingful outcome measures. These findings are promising for
the next step in our validation plan, which is to determine
the CFC’s sensitivity to clinically relevant changes over
time. The ultimate goal of the Catch-Cog study on the
CFC is to improve longitudinal clinical measurement in
early AD. The CFC is a concise measure with a relatively
short administration time, while being comprehensive
enough to have the potential to capture clinically meaningful
changes over time. Especially, the combination of cognitive
tests and an everyday functioning measure will advance the
clinical relevance of the composite score [42]. The CFC will
be more time efficient than traditional measures and provide
a more meaningful and sensitive outcome measures for
monitoring progression and evaluating future clinical trials.
This will eventually contribute to the still ongoing quest for a
disease-modifying or even preventive (drug) therapy against
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1. Systematic review: We aimed to assess test–retest
reliability, potential to be influenced by practice ef-
fects, and feasibility of use of our recently designed
cognitive-functional composite (CFC). We searched
PubMed for publications reporting on practice ef-
fects on cognitive tests that are included in the CFC.
2. Interpretation: We found moderate to high test–retest
reliability for all CFC subtests. We only found negli-
gible practice effects on one subtest in patients with
mild cognitive impairment or mild dementia due to
Alzheimer’s disease. The administration of the CFC
was perceived as feasible. We demonstrated that the
CFC is a stable and feasible measure and thereby
meets important quality metrics for clinically mean-
ingful outcomemeasures to assess changes over time.
3. Future directions: These findings are promising for
the next step in our validation plan: we will perform
a longitudinal construct validation study to deter-
mine the sensitivity of the CFC to clinically relevant
changes over time.
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